Literature DB >> 32411570

Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer.

Yiru Wang1,2, Ying Yan1,2, Mengying Yang1,2, Zhijun Yang1,2.   

Abstract

This study aimed to explore the expressions of signal transducer and activator of transcription 3 (STAT3) and a gene associated with retinoid-interferon induced mortality (Grim19) in epithelial ovarian cancer (EOC), and to determine their correlations with tumor progression and metastasis as well as the related mechanism. Ovarian tissue specimens resected through operation in our hospital were collected, and the correlations of Grim19 and STAT3 expressions with clinicopathological indexes were detected via immunohistochemistry (IHC) and Western blotting. Their positions in cells were observed through immunofluorescence. IHC assay results showed that STAT3 had the lowest expression level in the normal ovary, followed by those in benign ovarian tumor and borderline ovarian tumor (BOT), but it had high expression in EOC; The expression level of Grim19 was the lowest in EOC, followed by those in BOT and benign ovarian tumor successively, while it was highly expressed in the normal ovary; The expressions of STAT3 and Grim19 presented negative correlations in all kinds of ovarian tissues (p < 0.05). The expression level of STAT3 in EOC had no obvious correlations with FIGO staging or WHO classification (p > 0.05). The expression level of Grim19 in EOC in stage FIGO III-IV was higher than that in stage FIGO I-II (p < 0.05), Grim19 expression was not obviously associated with WHO classification (p > 0.05). The expressions of Grim19 and STAT3 in lymphatic metastasis lesion had significantly positive correlations with the primary lesion (p < 0.05). The Western blotting assay results were identical with the IHC results. The immunofluorescence demonstrated that STAT3 and Grim19 were mainly localized in the cytoplasm and they were colocalized in mitochondria. In conclusion, STAT3 presents high expression in EOC tissues while Grim19 is expressed in EOC tissues at a low level, which may be related to its interaction with STAT3 as well as progression, metastasis and poor prognosis of ovarian cancer. © King Abdulaziz City for Science and Technology 2020.

Entities:  

Keywords:  Grim19; Metastasis; Ovarian cancer; Prognosis; Progression; STAT3

Year:  2020        PMID: 32411570      PMCID: PMC7214566          DOI: 10.1007/s13205-020-02237-x

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  27 in total

Review 1.  The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.

Authors:  Nakho Chang; Sun Hee Ahn; Doo-Sik Kong; Hye Won Lee; Do-Hyun Nam
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 3.  Epithelial ovarian cancer.

Authors:  Stephanie Lheureux; Charlie Gourley; Ignace Vergote; Amit M Oza
Journal:  Lancet       Date:  2019-03-23       Impact factor: 79.321

Review 4.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

Review 5.  The potential and controversy of targeting STAT family members in cancer.

Authors:  Yannick Verhoeven; Sam Tilborghs; Julie Jacobs; Jorrit De Waele; Delphine Quatannens; Christophe Deben; Hans Prenen; Patrick Pauwels; Xuan Bich Trinh; An Wouters; Evelien L J Smits; Filip Lardon; Peter A van Dam
Journal:  Semin Cancer Biol       Date:  2019-10-09       Impact factor: 15.707

Review 6.  Acquired chemotherapy resistance in ovarian cancer.

Authors:  E L Christie; D D L Bowtell
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

7.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

8.  GRIM-19 represses the proliferation and invasion of cutaneous squamous cell carcinoma cells associated with downregulation of STAT3 signaling.

Authors:  Na Wu; Haiying Hui; Li Cui; Fan Yang
Journal:  Biomed Pharmacother       Date:  2017-10-06       Impact factor: 6.529

9.  Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.

Authors:  V Ghirardi; M C Moruzzi; N Bizzarri; V Vargiu; M D'Indinosante; G Garganese; T Pasciuto; M Loverro; G Scambia; A Fagotti
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

10.  Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.

Authors:  Mauricio S Caetano; Maya Hassane; Hieu T Van; Emmanuel Bugarin; Amber M Cumpian; Christina L McDowell; Carolina Gonzalez Cavazos; Huiyuan Zhang; Shanshan Deng; Lixia Diao; Jing Wang; Scott E Evans; Carmen Behrens; Ignacio I Wistuba; Susan A W Fuqua; Huang Lin; Laura P Stabile; Stephanie S Watowich; Humam Kadara; Seyed Javad Moghaddam
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.